RayRay - I think what you are missing is that the $80 million is essentially pure profit to a large pharma looking to beef up their pipeline. The synergy of rolling Avanir's drugs into their pipeline eliminates the majority of Avanir's expenses. Additionally, $80 million seems pretty low given that we are currently at a $70 million run rate. Where did you get the figures and how close have each of these analyst been with their past predictions? If an analyst has been off by by more then a couple of percent each quarter they should not even be included in the estimates.
Putting all that together, especially
considering the analysts expect
to start fiscal yr 2014 October, 2013 with a loss,
it would seem the
average analyst would call for
breakeven to be about December, 2013.
They must be expecting expenses to go up a
lot in fiscal yr 2014.